CDC: ‘The Decision to Vaccinate Is a Personal One’
A recent CDC statement may signal a shift in the agency's longstanding practice of advocating vaccinations for infectious diseases like measles.
Tag: vaccine RSV
All
Latest
CDC: ‘The Decision to Vaccinate Is a Personal One’
A recent CDC statement may signal a shift in the agency’s longstanding practice of advocating vaccinations for infectious diseases like measles.
Read More
RSV Vaccine Program for Seniors Cut Hospitalizations by 62%
An RSV vaccine program targeted at seniors in Scotland found 68% of adults aged 75-79 were vaccinated which led to a 62% reduction in RSV-related hospitalizations.
Read More
FDA Mandates Guillain-Barré Syndrome Warning for Two RSV Vaccines
The FDA has required Guillain-Barré syndrome warnings to be added to prescribing information for RSV vaccines Abrysvo and Arexvy.
Read More
American Confidence in RSV Vaccines Rises, Survey Finds
A new Annenberg Public Policy Center survey reveals evolving public attitudes toward vaccines—including RSV, flu, COVID-19, and MMR—in the United States.
Read More
COVID-19, Flu and RSV Shots − An Epidemiologist Explains Why All Three Matter This Fall
Epidemiologist Annette Regan explains why officials recommend that people get these shots over the coming months.
Read More
Americans’ Willingness to Get COVID-19 Vaccines Declines, Survey Finds
A survey found that 44% of Americans are likely to get a yearly COVID-19 vaccine if recommended by the CDC, a drop from 52% just eight months earlier.
Read More
ACP Urges Adults to Get Recommended Vaccinations
The American College of Physicians is advising adults to get all recommended vaccines to protect against preventable diseases and reduce the spread of infection.
Read More
Pfizer’s RSV Vaccine Shows Promise in Immunocompromised Adults
Pfizer’s Abrysvo demonstrated a strong immune response and favorable safety profile in immunocompromised adults at high risk of severe RSV.
Read More
Merck’s Investigational RSV Shot Protects Infants in Phase 2b/3 Trial
The trial showed that clesrovimab reduced RSV-related respiratory infections in infants through day 150.
Read More
Under 75? CDC Revises RSV Vaccine Recommendations for High-Risk Only
The CDC’s updated guidance recommends vaccination only for high-risk adults aged 60-74, while strengthening its advice for adults 75 and older.
Read More
FDA Expands Approval of Arexvy for Adults Age 50-59
GlaxoSmithKline’s RSV vaccine Arexvy is now available for at-risk adults age 50-59 in addition to those age 60 and older.
Read More
Tool Identifies Newborns at Highest Risk for Severe RSV
Researchers have created a new tool to identify newborns at the highest risk for severe RSV, enhancing the prioritization of immunoprophylaxis during shortages.
Read More
Most Pregnant Women Open to RSV Vaccine to Protect Infants, Survey Finds
A nationwide survey revealed that 54% of individuals who are pregnant or trying to become pregnant are interested in the RSV vaccine.
Read More
RSV Vaccine Added to ACIP 2024 Adult Immunization Schedule
The Advisory Committee on Immunization Practices has released its 2024 Recommended Adult Immunization Schedule which includes four new vaccines.
Read More
RSV Can Infect Nerve Cells and Enter Spinal Cord
Long thought to only infect the respiratory tract, a new study has found that RSV can infect nerve cells, cause nerve damage, and enter the spinal cord, potentially granting access to the central nervous system.
Read More
Full RSV Vaccination Could Cut Senior Hospitalizations by 91.7%
Respiratory syncytial virus vaccines recently approved for people 60 and older would dramatically reduce the disease’s burden of illness and death if they were widely adopted like annual influenza vaccines, a Yale University study finds.
Read More
Five Pharma Approvals from 2023
In some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
Read More
Promising Data for Arexvy RSV Vaccine for Adults 50-59
GlaxoSmithKline announced positive preliminary results from its phase III trial of its Arexvy RSV Vaccine in adults aged 50 to 59.
Read More
RSV Monoclonal Antibody in Short Supply
Sanofi issued an advisory to notify healthcare providers and consumers of a “unprecedented” and “higher than anticipated” demand for its recently-approved RSV monoclonal antibody, nirsevimab-alip (Beyfortus).
Read More
CDC Endorses Pfizer’s Maternal RSV Vaccine to Shield Newborns
Members of the Advisory Committee on Immunization Practices voted 11-1 to recommend the maternal RSV vaccine for pregnant people to prevent RSV lower respiratory tract infection in infants.
Read More
Are Older Americans Ready for an RSV Vaccine? New Poll Reveals Insights
The University of Michigan conducted a poll to gauge awareness and interest among older Americans regarding newly introduced RSV vaccines.
Read More
FDA Approves First RSV Vaccine for Use During Pregnancy
The US FDA expanded Pfizer’s Abrysvo (RSV vaccine) for use during pregnancy to prevent LRTD caused by RSV in infants from birth through 6 months of age.
Read More
Most Infants Receiving ICU-level Care for RSV Were Previously Healthy
A CDC-supported study found the majority of infants admitted to the intensive care or high acuity unit for RSV during fall 2022 were previously healthy and born at term.
Read More
CDC Recommends Beyfortus RSV Vaccine for Infants
CDC is recommending the novel RSV vaccine Beyfortus (nirsevimab, Sanofi and AstraZeneca) starting this fall to help protect all infants under 8 months and some older babies at increased risk of severe illness caused by respiratory syncytial virus.
Read More